CDK4 and breast cancer: Targeting this cell cycle cascade was found to be critical to overcome endocrine resistance and supported the clinical investigation of CDK4/6 inhibitors (CDK4/6i; palbociclib, ribociclib, and abemaciclib) in combination with ET in ER+ BC.